Late-Breaking Clinical Trial Results Announced at The VEINS 2023
Below are highlights of this morning's 4 late-breaking clinical trial presentations.
- Below are highlights of this morning's 4 late-breaking clinical trial presentations.
- These favorable clinical outcomes highlight the need for randomized controlled trial data comparing MT with standard of care anticoagulation treatment.
- In the second phase of the trial, 60 participants will be enrolled 1:1 in a dual-blinded, randomized controlled trial (RCT).
- Of the 21 patients followed at 1 month, 19 (90.5%) had fully compressible and two had partially compressible common femoral veins.